EN | FR
Company :: News, Events and Press
Press Releases
TherapyEdge ABL SA and BioLiveScale SA are pleased to announce a co-sponsoring of the next Symposium on the management of HIV/HBV-HCV co-infections.
Luxembourg October 06, 2009
TherapyEdge ABL SA and BioLiveScale SA are pleased to announce a co-sponsoring of the next Symposium on the management of HIV/HBV-HCV co-infections which will be held at the HILTON hotel in Yaoundé (CAMEROUN) on Thursday, the 23rd of October, 2009 during the "XIIes JOURNEES DE GASTRO-ENTEROLOGIE D’AFRIQUE FRANCOPHONE – JGAF & XXe CONGRES NATIONAL DE LA SOCIETE CAMEROUNAISE DE GASTRO-ENTEROLOGIE".
The program of the symposium will be the following:
Program:
Président : Christian Tzeuton, Douala (Cameroun) ; co-président : Alain Attia, Abidjan(Côte d’Ivoire)
18h-18h30 - Aspects pratiques des tests non-invasifs de fibrose hépatique : Paul Calès, Angers (France)
18h30-19h - Prise en charge pratique des co-infections : Serge Tchamgoué, Libourne (France et Cameroun)
19h-19h30 - Du concept de Disease Management au dossier informatisé patient : Paul Calès, Angers (France)
19:30 : - Cocktail
ABL SA is pleased to announce the United States Patent & Trademark Office (USPTO) issued on September 15th 2009, the Ex Parte Reexamination Certificate for the Barry et al US patent N° 6,081,786
Luxembourg October 05, 2009
See the Ex Parte Reexamination Certificate here 
ABL and Evivar Medical enter into Agreements to form a global strategic partnership and IP cross-licensing for disease management and personalized healthcare of Hepatitis B and HIV infections
Luxembourg October 05, 2009
LUXEMBOURG & MELBOURNE, Australia--(BUSINESS WIRE)--ABL, S.A. and Evivar Medical Pty Ltd today announced the completion of agreements to cross-licence their respective intellectual property portfolios and to form strategic alliances based on the use of their proprietary disease management platforms in HIV and Hepatitis (namely TherapyEdge, ViroScore and SeqHepB).The agreements will include joint strategies in development and commercialisation of their products, and joint research efforts to develop new products.
See the Full Release Presentation Here
TherapyEdge and RightToCare Successfully Launch the New TherapyEdge™ Down Referral Software Patient Management System
Johannesburg July 07, 2009
TherapyEdge ABL and Right to Care are pleased to announce the first year experience of down referral (DR) using its proprietary patient management electronic record system named TherapyEdge™ Down Referral Module, presented at the 4th Southern African AIDS conference (Durban, April 2009).
Advanced Biological Laboratories Patent Licensing Technologies SARL Enters U.S. Patent License Agreement With Viralliance Inc.
Luxembourg July 04, 2008
ABL Patent Licensing Technologies, SARL, a subsidiary of Advanced Biological Laboratories SA (ABL) entered into a patent licensing agreement with Viralliance Inc. (VI). As per the scope of the patent license agreement, ABL has granted a non-exclusive, royalty-bearing license to VI to use the ABL patent portfolio for guiding and ranking the selection of a therapeutic regimen for a given patient. The other terms of the agreement are confidential.
TherapyEdge, ABL and MSH Enter into Agreement to Collaborate on Integration of Software for the Management of HIV, Tuberculosis
Cambridge, MA, and Luxembourg (PRWeb) December 7, 2007
TherapyEdge, Inc., and Advanced Biological Laboratories (ABL), S.A., and Management Sciences for Health, Inc. (MSH) today announced the completion of an agreement to develop an interface between ABL's proprietary TherapyEdge and MSH's proprietary RxSolution. Development of an interface between the two software products will allow for a fully integrated IT solution for clinical services and medicines supply management. The interface will also enable the issuance of fully automated global reporting, consistent with existing and future requirements from various stakeholders such as the World Health Organization, (WHO), the Joint United Nations Programme on HIV/AIDS (UNAIDS), and the United States Agency for International Development (USAID), Clinton Foundation, and the Bill and Melinda Gates Foundation.
TherapyEdge (ABL group) and TCELS To Cooperate for the National HIV/AIDS Surveillance Program in Thailand Using The TherapyEdge-ViroScoreTM System
Luxembourg May 20, 2008
The Thailand Centre of Excellence for Life Sciences (TCELS, Bangkok (Thailand)), TherapyEdge Inc. (TE; Boston (MA)) and Advanced Biological Laboratories (ABL), S.A (Luxembourg), today announced the completion of a partnership agreement to set up a national, multi-centric, prospective HIV/AIDS surveillance program in Thailand for the 3 forthcoming years.
Under the terms of the agreement, ABL-TE will equip the fifteen major hospitals and reference laboratories in Thailand with the Thai Edition of the TherapyEdge-ViroScoreTM platform. TCELS and ABL-TE will jointly fund the surveillance system for the program. Cybeles Life Science (Germany) did lead the communication of the project between the parties and the local subsidiary will provide technical support. The Pharmacogenomics Group of TCELS, directed by Prof. Wasun Chantratita will conduct the daily operations and will handle the studies of data collected through this network of excellence. All the partners will exploit associated know-how.
"The TherapyEdge and ViroScoreTM Suite systems, Thai Edition, will be the main software platform for HIV/AIDS surveillance in Thailand which now allows us to have an electronic patient database. It will be the key for developing more efficient and safer therapies. This will also reduce the time and procedures to discover and develop new drugs resulting in lower overall costs and expenses in medications for the public health system”, said Dr Tongchai Thavichachart, CEO of TCELS.
TherapyEdge, ABL and MSH Enter into Agreement to Collaborate on Integration of Software for the Management of HIV, Tuberculosis
Cambridge, MA, and Luxembourg (PRWeb) December 7, 2007
TherapyEdge, Inc., and Advanced Biological Laboratories (ABL), S.A., and Management Sciences for Health, Inc. (MSH) today announced the completion of an agreement to develop an interface between ABL's proprietary TherapyEdge and MSH's proprietary RxSolution. Development of an interface between the two software products will allow for a fully integrated IT solution for clinical services and medicines supply management. The interface will also enable the issuance of fully automated global reporting, consistent with existing and future requirements from various stakeholders such as the World Health Organization, (WHO), the Joint United Nations Programme on HIV/AIDS (UNAIDS), and the United States Agency for International Development (USAID), Clinton Foundation, and the Bill and Melinda Gates Foundation.
Advanced Biological Laboratories (ABL) and PharmAccess Foundation Enter Licensing Agreement to Support the PASER Study
Luxembourg and Amsterdam, The Netherlands, September 13, 2007
Advanced Biological Laboratories (ABL), S.A., and PharmAccess Foundation today announced the completion of a licensing agreement for the customization of ABL’s proprietary TherapyEdge HIV ViroScoreTM Suite platform to support PharmAccess’ African Studies to Evaluate Resistance (PASER), as part of the LAASER-HIV/AIDS Program: Linking African and Asian Societies for an Enhanced Response to HIV/AIDS.
TherapyEdge HIV ViroScoreTM Suite is a HIV-1 sequence database used by clinicians and virologists in over 36 countries to store, organize and analyze HIV resistance information and to link the clinical and virological backgrounds of individuals. In some settings, it allows for the selection of personalized optimal HIV antiretroviral therapy using antiretroviral resistance interpretation systems (six international expert peer reviewed algorithms). “We are very happy to collaborate with PharmAccess’ dedicated, key-opinion leaders in their efforts to expand access to quality, scientifically sound HIV/AIDS care and treatment in the context of general healthcare in resource limited regions of the world, while continuing to strengthen the knowledge and the science embedded in TherapyEdge HIV ViroScoreTM Suite technology,” said Jean-Claude Schmit, MD, PhD, Chief Scientific Officer of TherapyEdge-ABL.
Advanced Biological Laboratories SA (ABL, S.A) licenses Stanford HIV resistance interpretation algorithm - adds to ViroScoreTM Suite genetic sequence database and analysis engine.
DURHAM, NC and LUXEMBOURG, 30 March, 2005
Advanced Biological Laboratories SA (ABL, S.A) licenses Stanford HIV resistance interpretation algorithm to add to their ViroScoreTM Suite genetic sequence database and analysis engine.
The ViroScoreTMr HIV report is part of the ViroScoreTM Suite which provides decision support to HIV doctors by helping them select the best therapy for an HIV patient based on the past and current resistance to HIV drugs. The report has picked up a lot of support from opinion leaders in HIV clinical research as it offers a global interpretation based on research from six leading research centers across the world.
Advanced Biological Laboratories SA (ABL, S.A) acquires majority control of TherapyEdge Inc.; Acquisition adds key Biotech patent and related products.
DURHAM, NC and LUXEMBOURG, 14 February, 2005
ABL to integrate TherapyEdge-HIV product functionality into existing product line and license IP to leading diagnostic and laboratory companies.
Luxembourg and Durham, NC - February 14, 2005: ABL, SA (A Luxembourg Company) acquired majority control of TherapyEdge Inc.(Durham, NC) and its strategic intellectual property (IP), including seminal patents on computer decision support for treatment of complex diseases. Also acquired is the TherapyEdge-HIV Clinical Decision Support (CDS) and patient management software which offers guidance to physicians and care givers on complex therapies for diseases such as HIV/AIDS, TB, Hepatitis and complex diseases. The financial details of the deal were not disclosed. See the Full Release Here
Evidence Medical, LLC and Advanced Biological Laboratories SA Complete Licensing Agreement of Seminal Information Technology Related Medical Patents.
BOSTON and LUXEMBOURG, 22 November, 2004
Evidence Medical, a Delaware limited liability company, and Advanced Biological Laboratories (a Luxembourg resident company) have announced an exclusive license agreement in which Evidence Medical acquired exclusive rights to ABL’s ‘decision support’ patents in exchange for cash and a limited license back to ABL. Financial and other terms were not disclosed. Download a PDF of the full release.
Evidence Medical Announces Licensing Agreement with Virco BVBA
BOSTON, 22 November, 2004
Evidence Medical, a Delaware limited liability company and the exclusive licensee of seminal IT-related medical therapeutics and diagnostic patents from Advanced Biological Laboratories (Luxembourg), today announced that Virco BVBA (Mechelen, Belgium) has become the first commercial virology specialized diagnostic service provider to sublicense their patents. Financial and other terms were not disclosed. Download a PDF of the full release.
HIV European Union SPREAD Committee Selects the Web Based Platform HIV LogiCare (Now called TherapyEdge-HIV) from ABL SA.
Luxembourg, 02/02/2004
Advanced Biological Laboratories (ABL) SA. today announced that SPREAD, an official European Commission supported programme for the strategy to control spread of HIV drug resistance, has selected the HIV LogiCare software and platform technology developed by ABL, SA. Download a PDF of the full release.
Events
IAS 2005 :: Rio de Janerio, Brazil, 24-27 July 2005
IAS-2005 Website :: IAS has accepted 3 abstract submissions from ABL's research collaborations:
:: Gender Differences by ARV Initiates
:: ViroScoreTMr+Plus/Tipranavir interpretation
:: A Clinical Review of the TherapyEdge-HIV Version 3.2
44th ICAAC :: October 30, 31 and November 1, 2004
ABL Launched ViroScoreTM Suite 2.8, TherapyEdge-HIV 2.8 and the TherapyEdge-Rapid Capture systems while attending the 44th ICAAC meeting. Please see the products section of the website for more information: TherapyEdge-HIV, the ViroScoreTM Suite, the TherapyEdge-MyView patient interface and the TherapyEdge-Rapid Capture module.
News
ABL to expand product offering :: Oct. 30, 2004
ABL will launch two new products and updated versions of the TherapyEdge-HIV and ViroScoreTM Suite products while exhibiting at the 44th ICAAC meeting. TherapyEdge-HIV has entered it's fourth generation code base and is a very mature product. We have responded to users requests for a more complete patient record, included reports for the CDC and PEPFAR and modified the alerting system to be customizable. and tightly integrated our resistance interpretation system expanded the HIV specific patient record.
The ViroScoreTM Suite is now tightly integrated with TherapyEdge-HIV so users can now use the data from the ViroScoreTM Suite HIV virus sequence database in conjunction with the rich clinical data from TherapyEdge-HIV. The power of this combined data will foster new research and improve clinical care. This update includes light versions of TherapyEdge-HIV and ViroScoreTM Suite which will be available as web services on a monthly subscription basis.
Our first new product is the our TherapyEdge-MyView patient interface. We had many requests over the years from patients and patient groups to have access to the same patient records and online tools that were being used by their doctors, so it is exciting to see these come to fruition. When used in conjunction with a clinic using TherapyEdge-HIV, there is a secure messaging system between patients and their care givers.
The second product is the TherapyEdge-Rapid Capture module. This module of TherapyEdge-HIV is a direct response to the needs of hospitals and large HIV clinics who see a great number of patients each day and need a simple printed form and matching page in the system for rapid data entry. This system was designed to capture all the pertinent data required for proper patient care and accurate reporting for PEPFAR and CDC required indicators.
Previous ABL and TherapyEdge News
ABL Announces Availability of the ViroScoreTM Suite For Palm-OS based Handhelds - 07/01/2003 Download the PDF
The Rega Institute Signs Exclusive HIV Drug Resistance Interpretation License Agreement With Advanced Biological Laboratories - 12/04/2002 Download the PDF
Advanced Biological Laboratories Launches HIV LogiCare: A Web-Based HIV/AIDS Patient Care Monitoring System - 11/15/2002 Download the PDF
Update of HIV ViroScoreTM Sutie(R), Online HIV Drug Resistance Interpretation Algorithms - 09/06/2002 Download the PDF
Advanced Biological Laboratories' Information Technology Used in Many Reference Studies - 07/08/2002 Download the PDF
Advanced Biological Laboratories (ABL) launches Hepatitis C Door2DoorTM molecular diagnostic services in Europe - 02/05/2002 Download the PDF
Milestone in a global scientific agreement between ABL and the Rega Institute (Leuven, Belgium) - 10/11/2001 Download the PDF
Ronan Boulme joins Advanced Biological Laboratories - 09/14/2001 Download the PDF
i-Subtyping, online service that can subtype all your HIV sequences - 07/11/2001 Download the PDF
Difficulties with the use of genotypic testing for antiretroviral resistance lie interpreting the report - 07/03/2001. Download the PDF
Prelaunch and official launch - 06/01-22/2001 Download the PDF
ABL helps expand the number of SPREAD project sites :: October, 2004
See the press release below for detailed information on the SPREAD project or visit the project site at
ABL Launches TherapyEdge-HIV v2.5 :: July 16, 2004
ABL / TherapyEdge launch version 2.5 of the TherapyEdge-HIV patient management and decision support system. Updates include a new drug-drug and drug condition interaction and alerting system, customizable alerts, secure messages between system
ABL Launches TherapyEdge-HIV v2.0 :: May 19, 2004
2.0 is a major revision to the TherapyEdge-HIV patient management and decision support system. We moved to the industry standard SQL database and open source technologies for the front end system. This helped us meet the users requests to readily analyze and report on their data and integrate with laboratories, pharmacies and others. We also separated out the resistance reporting and decision support functionality into modules that that are options for the sites who need that level of functionality.
ABL wins the SPREAD project, a 22 country resistance surveillance study :: June, 2002
ABL was awarded the SPREAD project in an international competitive bid process.